Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome

    Research output: Contribution to journalLetterResearchpeer-review

  1. During infancy low levels of follicle-stimulating hormone may result in high rate of germ cell apoptosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increments in DNA-thioguanine level during thiopurine enhanced maintenance therapy of acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinicopathologic characteristics of Burkitt lymphoma of the head and neck in a non-endemic region-a Danish nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Systematic dissection of transcriptional regulatory networks by genome-scale and single-cell CRISPR screens

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Clonal hematopoiesis of indeterminate potential (CHIP) is suspected of being a risk factor for patients with cancer. This study aimed to assess the clinical consequences of CHIP in patients with lymphoma intended for high-dose chemotherapy and autologous stem-cell transplantation (ASCT) in a population-based setting. We identified 892 lymphoma patients who had undergone stem cell harvest at all transplant centers in Denmark. A total of 565 patients had an available harvest sample, which was analysed for CHIP by next-generation sequencing, and the median follow-up was 9.1 years. Of the patients who were intended for immediate ASCT, 25.5% (112/440) carried at least one CHIP mutation. In contrast to previous single-center studies CHIP was not associated with inferior overall survival (OS) in multivariate analyses. However, patients with mutations in genes of the DNA repair pathway (PPM1D, TP53, RAD21, BRCC3) had a significant inferior OS (HR after 1 year of follow-up 2.79, 95% confidence interval 1.71-4.56; p < 0.0001), which also was evident in multivariate analysis (p = 0.00067). These patients had also increased rates of therapy-related leukemia and admission to intensive care. Furthermore, in patients who did not undergo immediate ASCT, a significant inferior OS of individuals with DNA repair mutations was also identified (p = 0.003).

Original languageEnglish
JournalLeukemia
Volume34
Issue number12
Pages (from-to)3256-3268
Number of pages13
ISSN0887-6924
DOIs
Publication statusPublished - Dec 2020

ID: 61628523